Tumor recurrence and metastasis develop as a result of tumors' acquisition of anti-apoptotic mechanisms and therefore, it is necessary to develop novel effective therapeutics against metastatic cancers. In this study, we showed the differential TRAIL responsiveness of human prostate adenocarcinoma PC3 and human colon carcinoma KM12 cells and their… (More)
Figure 3 Down-regulation of c-FLIPL/S and Mcl-1 in TRAIL-treated metastatic cancer cells. PC3 and PC3-MM2 cells were treated with 2 or 10 ng/ml TRAIL for 6 h, and KM12 and KM12L4A cells were treated with 5 or 25 ng/ml TRAIL for 8 h. After TRAIL treatment, the mRNA expression level of c-FLIPL/S (FLIPL/S) was measured by quantitative real-time RT-PCR (A), and protein levels of FLIPL/S and Mcl-1 were measured by Western blot analysis (B), respectively. b-Actin (Actin) was used as a loading control.